Dashboard
Manage Tickers

RYTM


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

goldman-sachs-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-139
Goldman Sachs Maintains Buy on Rhythm Phar...
10/17/2025 17:21:28

Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target ...

morgan-stanley-maintains-overweight-on-rhythm-pharmaceuticals-raises-price-target-to-129
Morgan Stanley Maintains Overweight on Rhy...
10/16/2025 18:01:46

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price ta...

hc-wainwright--co-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-110
HC Wainwright & Co. Maintains Buy on Rhyth...
09/29/2025 10:31:24

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Buy and raises the...

morgan-stanley-maintains-overweight-on-rhythm-pharmaceuticals-raises-price-target-to-122
Morgan Stanley Maintains Overweight on Rhy...
09/25/2025 17:54:10

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Overweight and raises the price t...

jmp-securities-maintains-market-outperform-on-rhythm-pharmaceuticals-raises-price-target-to-142
JMP Securities Maintains Market Outperform...
09/25/2025 13:13:08

JMP Securities analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Market Outperform and raises...

goldman-sachs-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-138
Goldman Sachs Maintains Buy on Rhythm Phar...
09/24/2025 18:01:13

Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target ...

peering-into-rhythm-pharmaceuticalss-recent-short-interest
Peering Into Rhythm Pharmaceuticals's Rece...
09/11/2025 17:01:03

rhythm-pharmaceuticals-announces-the-fda-has-accepted-its-supplemental-new-drug-application-for-setmelanotide-to-treat-acquired-hypothalamic-obesity
Rhythm Pharmaceuticals Announces The FDA H...
08/20/2025 20:03:53

U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 --– E...

hc-wainwright--co-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-100
HC Wainwright & Co. Maintains Buy on Rhyth...
08/07/2025 11:58:45

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the ...

12-analysts-have-this-to-say-about-rhythm-pharmaceuticals
12 Analysts Have This To Say About Rhythm ...
08/06/2025 21:04:06

morgan-stanley-maintains-overweight-on-rhythm-pharmaceuticals-raises-price-target-to-109
Morgan Stanley Maintains Overweight on Rhy...
08/06/2025 16:30:58

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price ta...

jmp-securities-maintains-market-outperform-on-rhythm-pharmaceuticals-raises-price-target-to-135
JMP Securities Maintains Market Outperform...
08/06/2025 15:19:13

JMP Securities analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises ...

guggenheim-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-120
Guggenheim Maintains Buy on Rhythm Pharmac...
08/06/2025 14:56:41

Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target fr...

rhythm-pharmaceuticals-q2-eps-075-misses-064-estimate-sales-4850m-beat-4372m-estimate
Rhythm Pharmaceuticals Q2 EPS $(0.75) Miss...
08/05/2025 11:03:46

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

a-glimpse-into-the-expert-outlook-on-rhythm-pharmaceuticals-through-10-analysts
A Glimpse Into The Expert Outlook On Rhyth...
07/18/2025 18:00:39

canaccord-genuity-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-105
Canaccord Genuity Maintains Buy on Rhythm ...
07/18/2025 14:14:51

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target...

reported-saturday-rhythm-pharmaceuticals-reports-statistically-significant-bmi-reductions-in-children-and-adults-across-multiple-doses-and-subgroups-in-transcend-and-signal-trials
Reported Saturday, Rhythm Pharmaceuticals ...
07/14/2025 06:51:46

Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –- Full data fro...

leerink-partners-maintains-outperform-on-rhythm-pharmaceuticals-raises-price-target-to-102
Leerink Partners Maintains Outperform on R...
07/10/2025 20:41:15

Leerink Partners analyst Faisal Khurshid maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the pri...

oppenheimer-maintains-outperform-on-rhythm-pharmaceuticals-raises-price-target-to-110
Oppenheimer Maintains Outperform on Rhythm...
07/10/2025 18:02:10

Oppenheimer analyst Leland Gershell maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION